Last reviewed · How we verify
Colloids
Colloids is a Small molecule drug developed by University of Versailles. It is currently in Phase 3 development. Also known as: frozen fresh plasma.
Colloids are mixtures in which one substance, consisting of microscopically dispersed insoluble particles, is suspended throughout another substance. Examples of colloids include fat emulsions, which are used to treat various conditions such as Advanced Malignant Neoplasm, HIV, and Papulopustular Rosacea, as seen in clinical trials registered on ClinicalTrials.gov.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Colloids |
|---|---|
| Also known as | frozen fresh plasma |
| Sponsor | University of Versailles |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- Pain Experience Using Lidocaine Adrenaline Tetracaine (LAT) Gel Versus Lidocaine Infiltration for Laceration Repair in Adults (PHASE4)
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Comparing Chitosan Sponge With Hydrocolloid as Dressing for Split-thickness Skin Graft Donor Site Wounds (NA)
- A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults (PHASE1)
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) (PHASE3)
- Initial Resuscitation for Acute Kidney Injury in Cirrhosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colloids CI brief — competitive landscape report
- Colloids updates RSS · CI watch RSS
- University of Versailles portfolio CI
Frequently asked questions about Colloids
What is Colloids?
Who makes Colloids?
Is Colloids also known as anything else?
What development phase is Colloids in?
Related
- Manufacturer: University of Versailles — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: frozen fresh plasma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing